Lemnalol attenuates mast cell activation and osteoclast activity in a gouty arthritis model

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 2, 2015, Pages 274-285

  Lee, Hsin Pai ^a,b   Lin, Yen You ^a   Duh, Chang Yih ^a   Huang, Shi Ying ^a   Wang, Hui Min ^c   Wu, Shu Fen ^d   Lin, Sung Chun ^b   Jean, Yen Hsuan ^b   Wen, Zhi Hong ^a  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^d NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

cathepsin K; lemnalol; mast cells; matrix metalloproteinase 9; tartrate resistant acid phosphatase; transforming growth factor beta 1

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; COLCHICINE; GELATINASE B; LEMNALOL; SESQUITERPENOID; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; URATE; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; SESQUITERPENE; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE EDEMA; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; GOUT; MALE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; OSTEOCLAST; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; ANKLE; ANTHOZOA; ARTHRITIS, GOUTY; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EDEMA; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANKLE; ANKLE JOINT; ANTHOZOA; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, GOUTY; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; EDEMA; MALE; MAST CELLS; OSTEOCLASTS; RATS, WISTAR; SESQUITERPENES; URIC ACID;

EID: 84921653217     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12331     Document Type: Article

References (55)

1. Neogi T,. Clinical practice. Gout. N Engl J Med 2011; 364: 443-452.
2. Busso N, So A,. Mechanisms of inflammation in gout. Arthritis Res Ther 2010; 12: 206-213.
3. Dalbeth N, Haskard DO,. Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005; 44: 1090-1096.
4. Rosengren S, et-al. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 2010; 12: R65.
5. Schiltz C, et-al. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 2002; 46: 1643-1650.
6. Getting SJ, et-al. Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins. J Pharmacol Exp Ther 1997; 283: 123-130.
7. Kong YY, et-al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
8. Jansen TL,. Rheumatology meets radiology in the hot soup of Gutta. Arthritis Res Ther 2012; 14: 126-129.
9. Teitelbaum SL,. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.
10. Janssens K, et-al. Transforming growth factor-beta1 to the bone. Endocr Rev 2005; 26: 743-774.
11. Dalbeth N, et-al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 2008; 58: 1854-1865.
12. Sells Galvin RJ, et-al. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 1999; 265: 233-239.
13. Fava R, et-al. Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med 1989; 169: 291-296.
14. Hauschka PV, et-al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986; 261: 12665-12674.
15. Balooch G, et-al. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 2005; 102: 18813-18818.
16. Pfeilschifter J, Mundy GR,. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A 1987; 84: 2024-2028.
17. Duh CY, et-al. Steroids and sesquiterpenoids from the soft corals Dendronephthya gigantea and Lemnalia cervicorni. J Nat Prod 2004; 67: 1650-1653.
18. Kikuchi H, et-al. Anti-tumor activity of lemnalol isolated from the soft coral Lemnalia tenuis Verseveldt. Chem Pharm Bull (Tokyo) 1983; 31: 1086-1088.
19. Jean YH, et-al. Inducible nitric oxide synthase and cyclooxygenase-2 participate in anti-inflammatory and analgesic effects of the natural marine compound lemnalol from Formosan soft coral Lemnalia cervicorni. Eur J Pharmacol 2008; 578: 323-331.
20. Lin YC, et-al. Intrathecal lemnalol, a natural marine compound obtained from Formosan soft coral, attenuates nociceptive responses and the activity of spinal glial cells in neuropathic rats. Behav Pharmacol 2011; 22: 739-750.
21. Lee HP, et-al. Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression. Mar drugs 2013; 11: 99-113.
22. Roddy E, et-al. Gout. BMJ 2013; 347: f5648.
23. McQueen FM, et-al. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol 2012; 8: 173-181.
24. Perez-Ruiz F, et-al. Imaging of gout: findings and utility. Arthritis Res Ther 2009; 11: 232-239.
25. Coderre TJ, Wall PD,. Ankle joint urate arthritis (AJUA) in rats: an alternative animal model of arthritis to that produced by Freund's adjuvant. Pain 1987; 28: 379-393.
26. Lin YY, et-al. A soft coral-derived compound, 11-epi-sinulariolide acetate suppresses inflammatory response and bone destruction in adjuvant-induced arthritis. PLoS ONE 2013; 8: e62926.
27. Dahal BK, et-al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011; 12: 60-70.
28. Nigrovic PA, Lee DM,. Mast cells in inflammatory arthritis. Arthritis Res Ther 2005; 7: 1-11.
29. Fouilloux I, et-al. Mast cell activation and degranulation occur early during induction of periosteal bone resorption. Bone 2006; 38: 59-66.
30. Fang KC, et-al. Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest 1996; 97: 1589-1596.
31. Tchougounova E, et-al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-9296.
32. Lee DM, et-al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297: 1689-1692.
33. Sokoloff L,. The pathology of gout. Metabolism 1957; 6: 230-243.
34. Schlesinger N, Thiele RG,. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010; 69: 1907-1912.
35. Schett G,. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 2008; 41: 224-229.
36. Liu R, et-al. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum 2004; 50: 247-258.
37. Biosse-Duplan M, et-al. Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 2009; 174: 1426-1434.
38. Deyama Y, et-al. Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. Biochem Biophys Res Commun 2002; 298: 240-246.
39. Fang KC, et-al. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997; 272: 25628-25635.
40. Li MO, et-al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
41. Quinn JM, et-al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001; 16: 1787-1794.
42. Tang Y, et-al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-765.
43. Simard N, et-al. A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis. Arthritis Res Ther 2006; 8: R125.
44. Chu SC, et-al. The clinical significance of gelatinase B in gouty arthritis of the knee. Clin Chim Acta 2004; 339: 77-83.
45. Hsieh MS, et-al. Expression of matrix metalloproteinase-9 (gelatinase B) in gouty arthritis and stimulation of MMP-9 by urate crystals in macrophages. J Cell Biochem 2003; 89: 791-799.
46. Schweyer S, et-al. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows Arch 2000; 437: 534-539.
47. Gri G, et-al. Mast cell: an emerging partner in immune interaction. Front Immunol 2012; 3: 120. doi: 10.3389/fimmu.2012.00120.
48. Katz WA, Schubert M,. The interaction of monosodium urate with connective tissue components. J Clin Invest 1970; 49: 1783-1789.
49. Muehleman C, et-al. Association between crystals and cartilage degeneration in the ankle. J Rheumatol 2008; 35: 1108-1117.
50. Tezuka K, et-al. Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 1994; 269: 15006-15009.
51. Inaoka T, et-al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995; 206: 89-96.
52. Suda T, et-al. Regulation of osteoclast function. J Bone Miner Res 1997; 12: 869-879.
53. Goldring SR, Gravallese EM,. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000; 12: 195-199.
54. Hie M, et-al. Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 2007; 41: 1045-1050.
55. Lubberts E, et-al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002; 46: 3055-3064.